Announcements Trials
Browse Landscape

Phase

Phase NA 34Phase 3 4Phase 2 2Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5Breast 5Thoracic 3Other hematologic neoplasm 3Genitourinary 3CNS 3Tumor-Agnostic 2Sarcoma 2Plasma cell 2Lymphoid 2Gynecologic 2Dermatologic 2Myeloid 1Endocrine 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Hereditary Breast and Ovarian Cancer Syndrome 1Breast Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 134pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Letrozole 28Drug Therapy 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23durvalumab 22Albumin-Bound Paclitaxel 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20Specimen Handling 20Filgrastim 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Blood Specimen Collection × Gynecologic × Clear all
NCT07276360 2026-03-27

HypoRTCx-UG

Uganda Cancer Institute

Phase 2 Recruiting
278 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT01333748 2012-07-13

EXSAL

Centre Francois Baclesse

Phase 2 Completed
530 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡